Gardasil (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022

Summary

The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most significant has been the inclusion of males in routine vaccine recommendations in some countries. The current HPV vaccines market is dominated by one major player, Merck's Gardasil, with GlaxoSmithKline's (GSK's) HPV vaccine Cervarix providing the only competition. The introduction of Merck's nine-valent vaccine (V503) is set to change the future landscape of the HPV vaccines sector.

In 2006 Gardasil (marketed as Silgard in Germany) became the first vaccine approved for prophylactic protection against HPV infection. Gardasil was primarily developed and marketed by Merck, under license from Australian biotechnology company CSL, which markets the vaccine in Australia and New Zealand. Gardasil is a quadrivalent vaccine containing recombinant virus-like particles (VLPs) of the L1 capsid protein from the HPV strains 6, 11, 16 and 18, combined with an aluminum adjuvant (amorphous aluminum hydroxyphosphate sulfate).

Scope

- Overview of HPV, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Gardasil including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Gardasil for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Canada and Australia

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for HPV
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Gardasil performance
- Obtain sales forecast for Gardasil from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Canada and Australia)

Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Symptoms
4 Vaccination Recommendations and Coverage Rates
4.1 Vaccination Recommendations Overview
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
6 Gardasil
6.1 Overview
6.2 Efficacy
6.3 Safety
6.4 SWOT Analysis
6.5 Forecast
7 Appendix
7.1 Bibliography
7.2 Abbreviations
7.3 Methodology
7.4 Forecasting Methodology
7.4.1 Vaccine Coverage
7.4.2 Vaccine Approval versus Routine Schedule Inclusion
7.4.3 General Pricing Assumptions
7.4.4 Individual Drug Assumptions
7.5 Physicians and Specialists Included in this Study
7.6 About the Author(s)
7.6.1 Author(s)
7.6.2 Therapy Area Director
7.6.3 Global Head of Healthcare
7.7 About Us
7.8 Disclaimer

1.1 List of Tables
Table 1: Histological Progression Towards Cervical Cancer
Table 2: Diseases Associated with HPV Infection and Their Associated Symptoms
Table 3: HPV Vaccine Recommendation Agencies by Country
Table 4: Targeted Group(s) for Recommended Immunization and Most-Administered HPV Vaccine by Country in the Global Markets, 2014
Table 5: Marketed Vaccines for HPV, 2014
Table 6: Product Profile - Gardasil
Table 7: Phase III Efficacy Trials - Gardasil
Table 8: Safety Profile - Gardasil
Table 9: Gardasil SWOT Analysis, 2014
Table 10: Global Sales Forecasts ($m) for Gardasil, 2012-2022
Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Gardasil (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022
Web Address: http://www.researchandmarkets.com/reports/2881942/
Office Code: SC6I5RE7

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 3495</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 6990</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 10485</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [Mr, Mrs, Dr, Miss, Ms, Prof]
First Name: 
Last Name: 
Email Address: *
Job Title: 
Organisation: 
Address: 
City: 
Postal / Zip Code: 
Country: 
Phone Number: 
Fax Number: 

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: ________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World